SLRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	6 211.00
Average Volume	109 798
Market Cap	2.13M
EPS	$0 ( 2024-03-25 )
Next earnings date	( $-6.70 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0100 (2.03%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Arthur David J.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Rosenblum Mark J	Buy	22 500	Stock Option (right to buy)
2024-02-20	Mcvicar William K.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Mccreedy Bruce J Jr.	Buy	20 500	Stock Option (right to buy)
2024-02-20	Lieber Jonathan I	Buy	20 500	Stock Option (right to buy)

INSIDER POWER
100.00
Last 99 transactions
Buy: 2 809 420 \| Sell: 0

Salarius Pharmaceuticals Correlation

10 Most Positive Correlations
OTLY	0.838
TCON	0.807

10 Most Negative Correlations
BNIXU	-0.818

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Salarius Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-10 051.00 (0.00 %)
EPS:	$-3.84

Q4	2023
Revenue:	$0
Gross Profit:	$-1 105.00 (0.00 %)
EPS:	$-0.220

Q3	2023
Revenue:	$0
Gross Profit:	$-5 608.00 (0.00 %)
EPS:	$-0.650

Q2	2023
Revenue:	$0
Gross Profit:	$-1 669.00 (0.00 %)
EPS:	$-1.430

Financial Reports:

No articles found.

Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.